Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024
For the Full year, the company expects revenue of $2,635 million to $2,735 million, net loss per share of $1,10 to $0.80.
Market Closed -
Other stock markets
|
Pre-market 07:57:32 am | |||
11.83 USD | -3.82% | 11.82 | -0.08% |
May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
1st Jan change | Capi. | |
---|---|---|
-45.10% | 2.01B | |
+87.28% | 612M | |
+8.27% | 467M | |
-67.79% | 142M | |
-27.19% | 96.84M |